Zevra Therapeutics Inc
ZVRA
View Detailed Chart
8.600USD
+0.240+2.87%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
483.47MMarket Cap
14.25P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+2.87%
5 Days
-4.44%
1 Month
+3.49%
6 Months
-25.09%
Year to Date
-4.02%
1 Year
+9.14%
View Detailed Chart
TradingKey Stock Score of Zevra Therapeutics Inc
Currency: USD Updated: 2026-02-06Key Insights
Zevra Therapeutics Inc's fundamentals are relatively healthy, with industry-average ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 68 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 22.86.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Zevra Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Zevra Therapeutics Inc Highlights
StrengthsRisks
Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. It has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 132.38% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 23.61M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 23.61M.
Overvalued
The company’s latest PE is 14.25, at a high 3-year percentile range.
Held by PRFDX
Star Investor PRFDX holds 5.30K shares of this stock.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
22.857
Target Price
+173.41%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Zevra Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Zevra Therapeutics Inc Info
Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. It has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.
Ticker SymbolZVRA
CompanyZevra Therapeutics Inc
CEOMcfarlane (Neil F)
Websitehttps://zevra.com/
Related Instruments
+3.66%
+3.14%
+0.93%
+2.01%
+1.82%
+1.60%
-0.95%
+4.49%
+2.10%
+9.92%
+2.76%
+4.15%
+1.79%
+4.17%
+0.72%
+1.10%
+2.46%
0.00%
+0.51%
+0.54%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
68341.570
-1628.560 (-2.33%)
282.580
+22.390 (+8.61%)
2031.470
-20.260 (-0.99%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
